Moonmoon Kazi/LinkedIn
Jun 15, 2026, 12:46
Moonmoon Kazi: Climb Bio Presents Phase 1b ITP Trial Data at EHA 2026
Moonmoon Kazi, Sr. Medical Director at Climb Bio, shared a post on LinkedIn:
“It has been six months into my role at Climb Bio and I’m so grateful to be part of an organization with a clear, science‑driven vision for building a focused and differentiated pipeline.
Presenting preliminary data from our Phase 1b ITP trial was a meaningful milestone, reinforcing how thoughtful translational strategy and rigorous early clinical execution inform downstream pipeline decisions.
I’m energized by the clarity of purpose and the caliber of the team, and I look forward to helping advance programs with the potential to meaningfully impact patients.”
Stay updated with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering